Participant flow30

How many started, completed or left each group, period by period.

21 to 30 of 30

Period	Milestone	Group	Participants
Second Treatment Intervention Period	COMPLETED	Placebo Followed by GEn 1200 mg/Day	53
Second Treatment Intervention Period	COMPLETED	GEn 1200 mg/Day Followed by Placebo	61
Second Treatment Intervention Period	NOT COMPLETED	Placebo Followed by GEn 1200 mg/Day	6
Second Treatment Intervention Period	NOT COMPLETED	GEn 1200 mg/Day Followed by Placebo	3
Second Taper Period	STARTED	Placebo Followed by GEn 1200 mg/Day	53
Second Taper Period	STARTED	GEn 1200 mg/Day Followed by Placebo	61
Second Taper Period	COMPLETED	Placebo Followed by GEn 1200 mg/Day	53
Second Taper Period	COMPLETED	GEn 1200 mg/Day Followed by Placebo	61
Second Taper Period	NOT COMPLETED	Placebo Followed by GEn 1200 mg/Day	0
Second Taper Period	NOT COMPLETED	GEn 1200 mg/Day Followed by Placebo	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00748098/flow?page=2